Roivant sets price for new rare disease drug Lisraya at $35,000 a month
ROIV•Lisraya list price set at $35,000 a month
Roivant and partner Priovant Therapeutics' newly approved rare disease drug Lisraya will carry a list price of $35,000 for a 30-day supply, Roivant Chief Executive Matt Gline said on an analyst call on Friday.
